RPG Life Sciences Limited — Earnings Release 2021

Jan 25, 2021

==> picture [506 x 98] intentionally omitted <==

January 25, 2021

To,

The Manager Listing Department National Stock Exchange of India Limited Exchange Plaza, 5th Floor Plot No. C1, ‘G’ Block, Bandra-Kurla Complex Bandra (East), Mumbai 400 051.

BSE Limited Corporate Relationship Department Floor 25, P.J. Towers Dalal Street Mumbai 400 001.

Symbol: RPGLIFE

Scrip code: 532983

Dear Sirs,

Sub: Press Release - Financial Results

Please find enclosed herewith a copy of press release with respect to Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2020.

Kindly take the above on record.

Thanking you,

Yours faithfully, For RPG Life Sciences Limited

==> picture [75 x 28] intentionally omitted <==

Rajesh Shirambekar Head – Legal & Company Secretary Encl: as above

==> picture [81 x 78] intentionally omitted <==

==> picture [531 x 56] intentionally omitted <==

==> picture [160 x 78] intentionally omitted <==

Quarter 3 PBT grew by 64% Y‐o‐Y and 16% Q‐o‐Q. Revenue from operations grew by 14% Y‐o‐Y and 11% Q‐o‐Q.

Mumbai, 25[th] January, 2021 : RPG Life Sciences Limited has announced its financial results for the third quarter and nine months ending on 31[st] December, 2020.

				YoY Net Revenue from Operations	YoY PBT from Operations
Q3	FY	21	Highlights	Rs 107.60 crores – up from Rs 94.37	Rs 17.07 crores – up from Rs 10.41
				crores	crores
9M	FY	21	Highlights	Rs 296.38 crores – up from Rs 286.90	Rs 44.63 crores – up from Rs 33.31
				crores	crores

RPG Life Sciences, engaged in the manufacturing and marketing of pharmaceutical products, posted a jump in profits by 64% Y‐o‐Y and by 16% Q‐o‐Q for Q3 FY 21, resulting in maintaining the upward trajectory in EBITDA margins, which improved from 15.8% to 19.9% Y‐o‐Y. Revenue from Operations at Rs 107.60 crores registered a growth of 14% Y‐o‐Y and a growth of 11% Q‐o‐Q for Q3 FY 21. For 9M FY 21 too, EBITDA margins improved from 16.4% to 19.5% Y‐o‐Y.

Mr. Yugal Sikri, Managing Director, RPG Life Sciences Ltd. said, “The overall performance of the Company in the third quarter and nine months of this fiscal has been strong despite the magnitude of disruptions caused by the extended Covid‐19 pandemic. Profits grew by 64% and 34% respectively and EBITDA margins retained their upward trajectory Y‐o‐Y for both Q3 and 9 months. Revenue grew by 14% Y‐o‐Y and 11% Q‐o‐Q. We are focused on executing our turnaround strategy. This comprises of growth initiatives such as product portfolio augmentation, life cycle management of our current brand assets and sales force effectiveness and profitability improvement measures such as opex control, efficient manufacturing operations and sales hygiene.”

RPG Life Sciences Ltd (www.rpglifesciences.com):

RPG Life Sciences Ltd, part of RPG Enterprises, is an integrated pharmaceutical company operating in the domestic and international markets in the branded formulations, global generics and synthetic APIs space. The company is a research‐based pharmaceutical company, producing a wide range of quality, affordable medicines. Its brands are highly trusted by healthcare professionals and patients.

RPG Enterprises (www.rpggroup.com):

RPG Enterprises, established in 1979, is one of India’s fastest growing business groups with a turnover of US$ 4 Billion. The group has diverse business interests in the areas of Infrastructure, Tyres, Pharma, IT and Specialty as well as in emerging innovation‐led technology businesses.

Media Contact:

Sumeet Chatterjee

Senior Vice President – Corporate Brand and Group Communications +91 9820340650 | sumeet@rpg.in

==> picture [81 x 78] intentionally omitted <==